Retrospective studies and xenograft models suggest that HER2-targeted monoclonal antibody therapies might even be able to target both HER2-nonamplified cancer cells and cancer stem cell populations via antibody-dependent, cell-mediated cytotoxicity (ADCC) [25]. The gene discussed is ERBB2; the disease is cancer.